Expression profiles for 14-3-3 zeta and CCL20 in pancreatic cancer and chronic pancreatitis

Pathology Research and Practice

Volumn 210, Issue 6, 2014, Pages 335-341

  Klemm, Christoph ^a   Dommisch, Henrik ^b,c   Göke, Friederike ^b   Kreppel, Matthias ^a   Jepsen, Søren ^b   Rolf, Fimmers ^d   Dommisch, Klaus ^e   Perner, Sven ^b   Standop, Jens ^d,f  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e HELIOS KLINIKEN SCHWERIN   (Germany)

^f Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

Author keywords

14 3 3 zeta; Biomarker; CCL20; Chronic pancreatitis; Diagnosis; Pancreatic cancer; Prognosis

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PROTEIN 14 3 3; CCL20 PROTEIN, HUMAN; TUMOR MARKER; YWHAZ PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS CANCER; PROTEIN EXPRESSION; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PREDICTIVE VALUE; UPREGULATION; VERY ELDERLY;

14-3-3 PROTEINS; ADULT; AGED; AGED, 80 AND OVER; CHEMOKINE CCL20; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84899476213     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.01.001     Document Type: Article

References (55)

1. Abiko Y., Nishimura M., Kusano K., et al. Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. Arch. Oral Biol. 2003, 48:171-175.
2. Aitken A. 14-3-3 proteins: a historic overview. Semin. Cancer Biol. 2006, 16:162-172.
3. Batty G.D., Kivimaki M., Morrison D., et al. Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall Study. Cancer Epidemiol. Biomarkers Prev. 2009, 18:673-675.
4. Bhardwaj A., Marsh W.L., Nash J.W., et al. Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study. Arch. Pathol. Lab. Med. 2007, 131(April):556-562.
5. Beavon I.R. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur. J. Cancer 2000, 36:1607-1620.
6. Brimiene V., Brimas G., Strupas K. Differential diagnosis between chronic pancreatitis and pancreatic cancer: a prospective study of 156 patients. Medicina (Kaunas) 2011, 47:154-162.
7. Campbell A.S., Albo D., Kimsey T.F., et al. Macrophage inflammatory protein-3alpha promotes pancreatic cancer cell invasion. J. Surg. Res. 2005, 123:96-101.
8. Chung W., Dommisch H., Yin L., Dale B. Expression of defensins in gingiva and their role in periodontal health and disease. Curr. Pharm. Des. 2007, 13:3073-3083.
9. Dommisch H., Chung W.O., Rohani M.G., et al. Protease-activated receptor 2 mediates human beta-defensin 2 and CC chemokine ligand 20 mRNA expression in response to proteases secreted by Porphyromonas gingivalis. Infect. Immun. 2007, 75:4326-4333.
10. Dommisch H., Chung W.O., Jepsen S., et al. Phospholipase C, p38/MAPK, and NF-kappaB-mediated induction of MIP-3alpha/CCL20 by Porphyromonas gingivalis. Innate Immun. 2010, 16:226-234.
11. Dommisch H., Reinartz M., Backhaus T., et al. Antimicrobial responses of primary gingival cells to Porphyromonas gingivalis. J. Clin. Periodontol. 2012, 39:913-922.
12. Ferlay J., Parkin D.M., Steliarova-Foucher.E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
13. Fischer N., Göke F., Splitstösser V., et al. Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma. Biochem. Biophys. Res. Commun. 2012, 417(1):29-34.
14. Genkinger J.M., Spiegelman D., Anderson K.E., et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol. Biomarkers Prev. 2009, 18:765-776.
15. Ghadjar P., Coupland S.E., Na I.K., et al. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J. Clin. Oncol. 2006, 24:1910-1916.
16. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
17. Hedrick M., Lonsdorf A., Hwang S., Farber J. CCR6 as a possible herapeutic target in psoriasis. Expert Opin. Ther. Targets 2010, 14:911-922.
18. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
19. Hoon D.S., Ferris R., Tanaka R., et al. Molecular mechanisms of metastasis. J. Surg. Oncol. 2011, 103:508-517.
20. Howes N., Neoptolemos J.P. Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Gut 2002, 51:765-766.
21. Iwata T., Tanaka K., Inoue Y., et al. Macrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer. J. Surg. Oncol. 2012, 107(2):160-166.
22. Jäger A., Kunert D., Friesen T., et al. Cellular and extracellular factors in early root resorption repair in the rat. Eur. J. Orthod. 2008, 30:336-345.
23. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57:43-66.
24. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
25. Kimsey T.F., Campbell A.S., Albo D., et al. Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J. 2004, 10:374-380.
26. Klapman J., Malafa M.P. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 2008, 15:280-287.
27. Kleeff J., Kusama T., Rossi D.L., et al. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 1999, 81:650-657.
28. Kloppel G., Adsay N.V. Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch. Pathol. Lab. Med. 2009, 133:382-387.
29. Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: a review of the literature. Mutat. Res. 2009, 681:299-307.
30. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
31. Lillemoe K.D., Yeo C.J., Cameron J.L. Pancreatic cancer: state-of-the-art care. CA Cancer J. Clin. 2000, 50:241-268.
32. Lowenfels A.B., Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20:197-209.
33. Marchesi F., Monti P., Leone B.E., et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004, 64:8420-8427.
34. Matsuo Y., Ochi N., Sawai H., et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int. J. Cancer 2009, 124:853-861.
35. Matta A., Siu K.M., Ralhan R. 14-3-3 zeta as novel molecular target for cancer therapy. Expert Opin. Ther. Targets 2012, 16(5):515-523.
36. Nakao A., Ichihara T., Nonami T., Harada A., Koshikawa T., Nakashima N., Nagura H., Takagi H. Clinicohistopathologic and immunohistochemical studies of intrapancreatic development of carcinoma of the head of the pancreas. Ann. Surg. 1989, 209(February (2)):181-187.
37. Neal C.L., Yu D. 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert Opin. Ther. Targets 2010, 14:1343-1354.
38. Niemantsverdriet M., Wagner K., Visser M., Backendorf C. Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008, 27:1315-1319.
39. Nitsche C., Simon P., Weiss F.U., et al. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig. Dis. 2011, 29:235-242.
40. Olson S.H. Selected medical conditions and risk of pancreatic cancer. Mol. Carcinog. 2012, 51:75-97.
41. Olson S.H., Kurtz R.C. Epidemiology of pancreatic cancer and the role of family history. J. Surg. Oncol. 2013, 107:1-7.
42. Opdenakker G., van Damme J. Novel Monocyte Hemoattractants in Cancer 1999, 51-69. Totowa Human Press. B. Rollins (Ed.).
43. Rubie C., Frick V.O., Wagner M., et al. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand. J. Immunol. 2006, 63:468-477.
44. Rubie C., Frick V.O., Ghadjar P., et al. CCL20/CCR6 expression profile in pancreatic cancer. J. Transl. Med. 2010, 8:45.
45. Schutyser E., Struyf S., Van D.J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003, 14:409-426.
46. Shen J., Person M.D., Zhu J., et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004, 64:9018-9026.
47. Tjomsland V., Niklasson L., Sandström P., et al. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin. Dev. Immunol. 2011, 2011:212810. (Epub 6.12.2011). 10.1155/2011/212810.
48. Topilow A.A., Davis J.M., Vernick J.J., et al. Confirmation of a potential biomarker for early-stage pancreatic cancer. Cancer Biomark. 2011, 10:27-33.
49. Tzivion G., Gupta V.S., Kaplun L., Balan V. 14-3-3 proteins as potential oncogenes. Semin. Cancer Biol. 2006, 16:203-213.
50. Wang Z., Ma Q., Liu Q., et al. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br. J. Cancer 2008, 99:1695-1703.
51. Weger A.R., Lindholm J.L. Discrimination of pancreatic adenocarcinomas from chronic pancreatitis by morphometric analysis. Pathol. Res. Pract. 1992, 188(February (1-2)):44-48.
52. Wente M.N., Mayer C., Gaida M.M., et al. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 2008, 259:209-217.
53. Winter J.M., Yeo C.J., Brody J.R. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J. Surg. Oncol. 2012.
54. Zannis-Hadjopoulos M., Yahyaoui W., Callejo M. 14-3-3 cruciform-binding proteins as regulators of eukaryotic DNA replication. Trends Biochem. Sci. 2008, 33:44-50.
55. Zhang H., Zhong W., Zhou G., et al. Expression of chemokine CCL20 in ulcerative colitis. Mol. Med. Rep. 2012, 6:1255-1260.